ArticleBasic and clinical neuroscience2025
Protective Effects of Adipose-derived Stem Cell Exosomes vs Dexamethasone on Neuromotor Deficits in Focal Cerebral Ischemia.
Article in Basic and clinical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cerebral ischemia is a leading cause of mortality and long-term disability worldwide, characterized by restricted blood flow to the brain, resulting in inflammation, oxidative stress, and neuronal death. Current therapies, such as thrombolytics and corticosteroids, offer limited efficacy in reversing neuronal damage. Recent advances suggest that exosomes derived from mesenchymal stem cells (MSCs) may provide neuroprotective benefits through anti-inflammatory and regenerative mechanisms. This study aimed to evaluate the therapeutic effects of exosomes derived from adipose tissue-MSCs (AT-MSCs) compared to dexamethasone in a rat model of transient focal cerebral ischemia. Methods: Twenty adult male Wistar rats were randomly assigned to four groups: Sham, transient middle cerebral artery occlusion (MCAO) control, exosome-treated, and dexamethasone-treated. MACO was induced to simulate an ischemic stroke. Exosomes were administered intravenously, while dexamethasone was given intraperitoneally. Behavioral assessments (Bederson and Garcia scores), infarct volume (2,3,5-triphenyltetrazolium chloride [TTC] staining), serum inflammatory markers (nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), tumor necrosis factor-α [TNF-α], interleukin-6 [IL-6]), and histopathological changes (H&E and Nissl staining) were analyzed. Results: Exosome treatment significantly improved neurological function and motor performance compared to the MCAO group, with superior outcomes relative to dexamethasone. Exosomes markedly reduced infarct volume and inflammatory biomarker levels, and histological analyses revealed preserved neuronal structure and reduced necrosis. Nissl staining revealed a higher count of healthy neurons in the exosome group compared to the other treatment groups. Conclusion: Exosomes derived from AT-MSCs offer superior neuroprotective effects in ischemic brain injury compared to dexamethasone. Their multi-modal mechanisms-including anti-inflammatory, anti-apoptotic, angiogenic, and neuroregenerative effects-highlight their potential as a novel therapeutic approach for stroke management. Future research should focus on clinical translation, dosage optimization, and long-term safety evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.